Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04627246 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Oversightv5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 12 to confirmed 14
    • Study description expanded, about 136 words
    • Site details revised
    v4
  3. Study description revisedv3
  4. Eligibility criteria expanded, about 26 words
    • Study description expanded, about 72 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase Ib clinical trial using Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP) in order to stimulate/induce both innate and adaptive immunity by activating T-cells and Natural Killer (NK) cells, combined with standard of care (SOC) adjuvant chemotherapy, followed by nivolumab, an antibody against Programmed Cell Death 1 (PD-1), to maintain and boost the vaccine's effect in patients with non-metastatic resectable pancreatic adenocarcinoma
Trial Details
NCT Number NCT04627246
Lead Sponsor Centre Hospitalier Universitaire Vaudois
Conditions
(from sponsor)		 Pancreatic Adenocarcinoma
Related terms Adenocarcinoma, Neoplasms
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov